Clinical Trial Update: To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy. [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating QLM2010 for prevention of chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• QLM2010

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Chemotherapy-Induced Nausea and Vomiting | Phase 3 | Status: COMPLETED